Építés alatt – nem éles oldal
Belépés

NCT07205250Toborzás még nem indultKorai 1. fázis

Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial

WesternTheaterCommand

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. febr. 12.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

ABSTRACT Introduction Endovascular aortic arch repair (EAAR) and the endovascular reconstruction of arch branch vessels represent a new trend in managing aortic arch pathologies, due to advantages such as minimal invasiveness, rapid recovery, and fewer complications. However, stroke is a common and serious complication during EAAR procedures. Strategies for its prevention, including the question of whether antiplatelet therapy should be administered postoperatively, have not yet been reported. Methods and analysis This project is designed as a prospective, multicenter, double-blind, randomized controlled trial. Patients undergoing Endovascular Aortic Arch Repair (EAAR) will be randomly assigned to three groups: aspirin treatment for 3 months, 6 months, or 1 year. All three groups will be followed up on for over one year. The primary endpoint is the incidence of postoperative stroke, while secondary endpoints include the patency rate of reconstructed supra-aortic branches, the incidence of major bleeding complications, EAAR-related complications, and the incidence of postoperative cognitive impairment. The study aims to evaluate the efficacy and safety of aspirin in preventing stroke after EAAR. Furthermore, stratified analyses will be conducted based on factors such as reconstruction techniques, the number of reconstructed branch arteries, and the diameter of branch stents to explore their impact on stroke incidence post-EAAR. The clinical utility of aspirin in different subgroups will also be assessed to provide more precise and personalized treatment strategies for clinical practice. Ethics and dissemination This study has been approved by the Western Theater Command General Hospital and will be conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval has been obtained separately from all participating research centers. STRENGTHS AND LIMITATIONS OF THIS STUDY Endovascular aortic arch repair (EAAR) and endovascular reconstruction of the aortic arch branches have emerged as a new trend in managing aortic arch pathologies, owing to advantages such as minimal invasiveness, rapid recovery, and fewer complications. Stroke is a common and serious complication during EAAR procedures; however, strategies for its prevention, including the need for postoperative antiplatelet therapy, have not been well documented. This project aims to conduct a prospective, multicenter randomized controlled trial to evaluate the efficacy and safety of aspirin in preventing stroke following EAAR, thereby providing evidence for clinical decision-making and improving long-term patient outcomes. As the trial will be conducted in China, where the population is predominantly Han Chinese, the generalizability of the findings may be limited.

Állapot (regiszter)
Toborzás még nem indult
Fázis (regiszter)
Korai 1. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
224 (tervezett)
Első benyújtás
2025. szept. 25.
Kezdés
2026. febr. 20.
Elsődleges befejezés
2028. jan. 20.
Fő szponzor
The General Hospital of Western Theater Command
NCT-szám
NCT07205250

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · Korai 1. fázis
  • Tervezett résztvevők: 224
  • 2026. febr. 20. és az elsődleges befejezés (2028. jan. 20.) között
  • Nincs megadott helyszín, ország nélkül
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Patients who used medications affecting coagulation (e.g., warfarin, antiplatelet drugs) within 30 days before surgery;
  • Patients undergoing concurrent additional surgical procedures during the operation;
  • Patients participating in other drug or clinical studies that may interfere with the results of this research.

Más betegség

  • Patients with known allergies to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs);
  • Patients with bleeding tendencies or active bleeding;
  • Patients with a history of stroke;
  • Patients with severe multi-organ dysfunction or other critical illnesses;

Egyéb

  • Patients unable to comply with study protocols or complete postoperative follow-up;

Kiket keres a vizsgálat

  • Adult patients aged 18 years or older;
  • Diagnosed with type B or non-A non-B aortic dissection or thoracic aortic aneurysm according to the 2022 Chinese Expert Consensus on Stanford Type B Aortic Dissection;
  • Underwent total endovascular aortic arch repair at the participating center with concurrent intraoperative endovascular reconstruction of supra-arch branch arteries;
  • Signed the informed consent form and agreed to participate in this randomized controlled trial.

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.